It is observed that the combination of the leptin-tamoxifen stimulus generates a decrease in the antiproliferative capacity of tamoxifen, which leads to propose that leptin participates in the mechanism of resistance to tamoxifen treatment, commonly observed in patients with breast cancer and obesity. This evidence concerns the gene LEP and obesity disorder.